Money Matters, Simplified.
What Investors Think About Clarient
Thu, 05/08/2010 - 00:08 by Motley Fool
Together, we are all trying to build our fortunes by finding well-run companies at bargain-basement prices. But it takes work to scour earnings reports, scrutinize key data, and assess the competition.
To help you out, we've created a screen based on the massive data aggregated from the more than 165,000 investors competing on our Motley Fool CAPSplatform. Each quarter, we check in on select companies after they file a 10-Q and track community sentiment to help you see how your company is doing. Here's our CAPS community's sentiment on Clarient(Nasdaq: CLRT) both for this quarter and last (for comparison), as well as opinions on some related companies. Source: Motley Fool CAPS. Dates given are the posting dates of Clarient's most recent quarterly and/or annual reports to the SEC's website. Percentages are calculated from the number of members rating each company. A change in the community's approval (signified by four- and five-star ratings) or disapproval (one- and two-star ratings) could indicate that further research is in order. To help make your research easier… © 2010 UCLICK L.L.C.Metric Clarient West Pharmaceutical Services (NYSE:WST) Hansen Medical(Nasdaq: HNSN) Insulet(Nasdaq:PODD) This Quarter (8/3/2010): Price: $3.33 $35.07 $1.75 $15.07 % of Members Rating Outperform 90% 92% 95% 56% % of All-Star Members Rating Outperform 88% 87% 95% 75% CAPS Rating (out of 5) *** ** **** * Last Quarter (5/5/2010): Price: $3.05 $41.63 $2.66 $14.03 % of Members Rating Outperform 90% 91% 95% 55% % of All-Star Members Rating Outperform 91% 87% 95% 78% CAPS Rating (out of 5) **** ** **** *
